Primary prevention of breast cancer in high-risk women by monitoring epigenetic changes in nipple aspirates by van Diest, PJ et al.
BioMed  Central
Page 1 of 1
(page number not for citation purposes)
BMC Proceedings
Open Access Meeting abstract
Primary prevention of breast cancer in high-risk women by 
monitoring epigenetic changes in nipple aspirates
PJ van Diest*, K Suijkerbuijk, H Meijrink, X Pan and E van der Wall
Address: Departments of Pathology and Internal Medicine, University Medical Center, Utrecht, The Netherlands
Email: PJ van Diest* - p.j.vandiest@umcutrecht.nl
* Corresponding author    
Breast cancer is the leading cause of cancer death in
women in the Western world. In the Netherlands, the inci-
dence is about 12,000 per year, which means that eventu-
ally every 9th woman will get breast cancer. The most
wellestablished breast cancer risk factor is the presence of
a germline mutation in the BRCA1 or BRCA2 genes, which
indicates a life time risk of 45–80% to get breast cancer.
Regular screening by clinical breast examination, mam-
mography and/or Magnetic Resonance Imaging (MRI) is
offered to these high-risk women, but one out of four
breast tumors are missed by these screening modalities.
The most effective form of primary prevention for high-
risk women is bilateral mastectomy, which gives a consid-
erable breast cancer risk reduction. As this procedure is
highly mutilating, many women opt out and those who
decide to undergo prophylactic surgery prefer to postpone
it as much as possible. This bears a significant risk of
developing invasive breast cancer in the meanwhile. In
contrast, the procedure has to be seen as over-treatment in
the 15%–55% of BRCA carriers that would never have
developed breast cancer. Up to now no procedures are
available that accurately predict who of these high-risk
women will and who will not develop breast cancer nor,
at what age the cancer will occur.
A new primary prevention modality for these high-risk
women could very well be found in the analysis of nipple
fluid. Nipple fluid, that contains breast epithelial cells,
free DNA and proteins secreted by them, is produced in
small amounts in the breast ducts of non-lactating women
and can be collected in a non-invasive way by vacuum-
aspiration. We were the first to prove that intranasal
administration of oxytocin enables harvesting nipple
fluid in almost all women.
We have set up a clinical trial for genetic monitoring of
nipple aspirates as a primary prevention tool for women
at high risk of breast cancer. To this end, we once yearly
harvest nipple fluid in patients with a hereditary predispo-
sition for breast cancer. In this nipple fluid, we assess pro-
moter methylation of a selected set of tumor suppressor
genes known to be involved in breast carcinogenesis. Such
epigenetic changes are non-specific, frequent and early
changes that are ideally suited for early detection of breast
cancer and its precursors. Patients will be monitored until
preventive or therapeutic surgery, and epigenetic changes
in nipple fluid will be correlated to histopathological
findings in the resection specimens. This will allow us to
establish in retrospect a specific pattern of epigenetic
changes that points to a progression from benign to
malignant and therefore indicate the time point for pro-
phylactic surgery in high-risk women. On the other hand,
should this pattern never occur, prophylactic surgery
could be completely avoided.
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